See the DrugPatentWatch profile for Ceftazidime
When does the patent for Ceftazidime-avibactam expire?
The primary patents for ceftazidime-avibactam are set to expire in the United States in 2027 [1]. However, secondary patents and exclusivities may extend market protection for the drug.
What is ceftazidime-avibactam used for?
Ceftazidime-avibactam is an antibiotic combination used to treat complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, that are caused by certain Gram-negative bacteria resistant to other treatments [2].
Who manufactures ceftazidime-avibactam?
Ceftazidime-avibactam is manufactured by AbbVie Inc. under the brand name Avycaz [2][3].
What is the significance of patent expiry for this drug?
Patent expiry for ceftazidime-avibactam would allow for the potential introduction of generic versions of the drug. This could lead to increased competition and potentially lower prices for the antibiotic. DrugPatentWatch.com tracks patent expiries for pharmaceuticals, including ceftazidime-avibactam [1].
Are there any other patents or exclusivities for ceftazidime-avibactam?
Beyond the primary patents expiring in 2027, there may be other patents covering different aspects of ceftazidime-avibactam, such as formulations, manufacturing processes, or specific indications. These secondary patents, along with regulatory exclusivities, can extend the period before generic competition is possible. Information regarding these additional patents and their expiry dates is available through resources like DrugPatentWatch.com [1].